Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca)
Subsidiary of AstraZeneca (AZN)
Assets
(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Acoramidis(Attruby) | Approved | Transthyretin (TTR)Small molecule | Transthyretin-Mediated Amyloidosis Transthyretin Amyloidosis with Cardiomyopathy |
Eculizumab(Soliris) | Approved | Complement C5Monoclonal antibody | Myasthenia GravisThrombotic MicroangiopathyParoxysmal Nocturnal Hemoglobinuria Generalized Myasthenia Gravis |
| Phase 2 | — | ANCA-Associated Vasculitis |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
Est. primary completion 2026-12-07 · NCT06724809 · CT.gov ↗
What to watch
2027 (2)
May 2027 (1)
Est. primary completion 2027-05-28 · NCT06449001 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
Est. primary completion 2028-04-15 · NCT04988386 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Acoramidis · AttrubyPhase 3Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
Est. primary completion 2031-10 · NCT06563895 · CT.gov ↗
What to watch
2037 (1)
November 2037 (1)
Acoramidis · AttrubyPhase 3Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related …
Est. primary completion 2037-11 · NCT07116473 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.